We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Merck KGaA Expands Distribution Deal with Roche (revised)
Read MoreHide Full Article
Germany-based Merck KGaA announced that it has expanded the distribution alliance with Roche Holding AG (RHHBY - Free Report) to include the enzyme portfolios of Kapa Biosystems (acquired by Roche in 2015) – polymerase chain reaction (PCR) and quantitative real-time PCR (qPCR).
Under the terms of the distribution agreement, Merck will gain the rights to all geographies expect the U.S., Brazil, and Japan. Financial details of the deal were, however, not disclosed.
The transition of portfolios is expected to be complete by Jan 1, 2017.
The agreement will strengthen the existing relationship between Merck KGaA and Roche, providing its customers broader access to novel products through distribution channels. The transition will significantly boost the company’s Life Science segment, which continues to be driven by the Sigma-Aldrich acquisition.
We note that Roche inked a global exclusive distribution agreement with Sigma-Aldrich, which was acquired by Merck KGaA in 2015. The Sigma-Aldrich acquisition offered Merck KGaA with a premier brand tools for genomics, proteomics and cell analysis.
A look at Merck KGaA’ year-to-date share price movement shows that the stock has consistently outperformed that of the Zacks classified Medical drugs industry. The company’s stock price rose 2.4% in year to date, compared with the industry’s 24.7% decline.
Zacks Rank & Key Picks
Investors looking for a couple of favorably placed stock in the health care sector may consider Cambrex Corporation and Vanda Pharmaceuticals, Inc. (VNDA - Free Report) . Both stocks sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Cambrex’s earnings estimates increased from $2.46 to $2.55 for 2016 and from $2.91 to $3.06 for 2017 over the last 60 days. The company posted a positive earnings surprise in three of the four trailing quarters with an average beat of 19.78%. Its share price has increased 6.4% year to date.
Vanda’s loss estimates narrowed from 68 cents to 56 cents for 2016, while its earnings estimates have increased from 16 cents to 17 cents for 2017 over the last 60 days. The company posted a positive earnings surprise in three of the four trailing quarters with an average positive surprise of 56.65%. Its share price has surged 76.7% year to date.
(We are reissuing this article to correct a mistake. The original article, issued December 2, 2016, should no longer be relied upon.)
Zacks’ Best Private Investment Ideas
In addition to the recommendations that are available to the public on our website, how would you like to follow all Zacks' private buys and sells in real time?
Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Starting today, for the next month, you can have unrestricted access. Click here for Zacks' private trades >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Merck KGaA Expands Distribution Deal with Roche (revised)
Germany-based Merck KGaA announced that it has expanded the distribution alliance with Roche Holding AG (RHHBY - Free Report) to include the enzyme portfolios of Kapa Biosystems (acquired by Roche in 2015) – polymerase chain reaction (PCR) and quantitative real-time PCR (qPCR).
Under the terms of the distribution agreement, Merck will gain the rights to all geographies expect the U.S., Brazil, and Japan. Financial details of the deal were, however, not disclosed.
The transition of portfolios is expected to be complete by Jan 1, 2017.
The agreement will strengthen the existing relationship between Merck KGaA and Roche, providing its customers broader access to novel products through distribution channels. The transition will significantly boost the company’s Life Science segment, which continues to be driven by the Sigma-Aldrich acquisition.
We note that Roche inked a global exclusive distribution agreement with Sigma-Aldrich, which was acquired by Merck KGaA in 2015. The Sigma-Aldrich acquisition offered Merck KGaA with a premier brand tools for genomics, proteomics and cell analysis.
MERCK KGAA Price | MERCK KGAA Quote
A look at Merck KGaA’ year-to-date share price movement shows that the stock has consistently outperformed that of the Zacks classified Medical drugs industry. The company’s stock price rose 2.4% in year to date, compared with the industry’s 24.7% decline.
Zacks Rank & Key Picks
Investors looking for a couple of favorably placed stock in the health care sector may consider Cambrex Corporation and Vanda Pharmaceuticals, Inc. (VNDA - Free Report) . Both stocks sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Cambrex’s earnings estimates increased from $2.46 to $2.55 for 2016 and from $2.91 to $3.06 for 2017 over the last 60 days. The company posted a positive earnings surprise in three of the four trailing quarters with an average beat of 19.78%. Its share price has increased 6.4% year to date.
Vanda’s loss estimates narrowed from 68 cents to 56 cents for 2016, while its earnings estimates have increased from 16 cents to 17 cents for 2017 over the last 60 days. The company posted a positive earnings surprise in three of the four trailing quarters with an average positive surprise of 56.65%. Its share price has surged 76.7% year to date.
(We are reissuing this article to correct a mistake. The original article, issued December 2, 2016, should no longer be relied upon.)
Zacks’ Best Private Investment Ideas
In addition to the recommendations that are available to the public on our website, how would you like to follow all Zacks' private buys and sells in real time?
Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Starting today, for the next month, you can have unrestricted access. Click here for Zacks' private trades >>